FDA: Label changes for finasteride expand list of adverse events
The FDA has announced changes to the professional labels for finasteride, 5 mg (Proscar), and finasteride, 1 mg (Propecia), to expand the list of sexual adverse events reported to the FDA, as some of these events have been reported to continue after the drug is no longer being used.
The new label changes include the following:
- a revision to the finasteride, 5 mg label, to include decreased libido that continued after discontinuation of the drug
- a revision to the finasteride, 1 mg, label to include libido disorders, ejaculation disorders, and orgasm disorders that continued after discontinuation of the drug
- a revision to both labels to include a description of reports of male infertility and/or poor semen quality that normalized or improved after drug discontinuation.
Despite the fact that clear causal links between finasteride (Propecia and Proscar) and sexual adverse events have not been established, the cases reviewed by the FDA suggest a broader range of adverse effects than previously reported in patients taking these drugs, the agency said in a statement.
For finasteride, 5 mg, the FDA reviewed 131 cases of erectile dysfunction and 68 cases of decreased libido associated with the use of the drug submitted to the drug sponsor’s worldwide safety database between 1992 and 2010. Regarding semen quality, 251 cases associated with the 1-mg dose were identified from the sponsor’s safety database. Of these, 13 contained enough information for the FDA to evaluate. Twenty-nine cases associated with finasteride, 5 mg, use were evaluated, of which only three involved men with BPH.
MORE ARTICLES IN THIS ISSUE
Pelvic floor muscle training is effective for treating adult women with urinary incontinence without risk of side effects, according to a recent report.
Compared with women who deliver via cesarean, women who deliver vaginally are 67% more likely to experience urinary incontinence up to 20 years after the birth and are almost three times as likely to be incontinent for more than 10 years, Swedish researchers report.
Compared with conformal radiation therapy, intensity-modulated radiation therapy (IMRT) was associated with fewer diagnoses of gastrointestinal adverse effects, hip fractures, and receipt of additional cancer treatments but more cases of erectile dysfunction in an analysis of three different types of radiation therapy used to treat localized prostate cancer.
For the second time in a month, urologists are being criticized for self-referred ancillary services?this time by radiologists for providing intensity-modulated radiotherapy (IMRT) treatment for prostate cancer patients in urologists' own radiation therapy centers.